ArticleBMJ open2021
Supplementation with
Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04769037 ("SINT1A" - Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity - A Study of the Global Platform for the Prevention of Autoimmune Diabetes), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"SINT1A" - Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity - A Study of the Global Platform for the Prevention of Autoimmune Diabetes ("GPPAD")
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Are Bifidobacterium Species Key Players in the Progression of Type 1 Diabetes? A Systematic Review.Endocrinology, diabetes & metabolism · 2025Pooled it
- ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes.Hormone research in paediatrics · 2024Guideline
- Determinants of Infant Participation and Non-Participation in Primary Prevention Trials.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2026Article
- Immune development in early life.Nature immunology · 2026Review
- Perspectives on prevention of type 1 diabetes and heterogeneities.Diabetologia · 2025Review
- Gut microbiota development across the lifespan: Disease links and health-promoting interventions.Journal of internal medicine · 2025Review
- From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes.Metabolites · 2025Review
- Changes in the Prevalence of Diabetes Ketoacidosis at the Onset of Type 1 Diabetes in Polish Children: A Comparative Analysis Between Two 9-Year Periods-2006-2014 and 2015-2023.Pediatric diabetes · 2025Article
- Gut microbiome shifts in people with type 1 diabetes are associated with glycaemic control: an INNODIA study.Diabetologia · 2024Article
- A Review of Stage 0 Biomarkers in Type 1 Diabetes: The Holy Grail of Early Detection and Prevention?Journal of personalized medicine · 2024Review
- Environmental Determinants of Islet Autoimmunity (ENDIA) longitudinal prospective pregnancy to childhood cohort study of Australian children at risk of type 1 diabetes: parental demographics and birth information.BMJ open diabetes research & care · 2024Article
- Bifidobacteria in disease: from head to toe.Folia microbiologica · 2024Review
- Screening and Prevention of Type 1 Diabetes: Where Are We?The Journal of clinical endocrinology and metabolism · 2023Review
- The countdown to type 1 diabetes: when, how and why does the clock start?Diabetologia · 2023Review
- The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness.Frontiers in immunology · 2023Review
- Maternal provisions in type 1 diabetes: Evidence for both protective & pathogenic potential.Frontiers in immunology · 2023Review
- Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials.Archives of disease in childhood · 2023Article
- Type 1 diabetes mellitus prevention.Pediatric endocrinology, diabetes, and metabolism · 2023Article
- Pathophysiology of Type 1 Diabetes and Gut Microbiota Role.International journal of molecular sciences · 2022Review
- Utilizing Modular Biobanking Software in Different Types of Biobanking Activities.Biopreservation and biobanking · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 11 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Global Platform for the Prevention of Autoimmune Diabetes-SINT1A Study is designed as a randomised, placebo-controlled, double-blind, multicentre, multinational, primary prevention study aiming to assess whether daily administration of METHODS AND ANALYSIS: Infants aged 7 days to 6 weeks from Germany, Poland, Belgium, UK and Sweden are eligible for study participation if they have a >10.0% expected risk for developing multiple beta-cell autoantibodies by age 6 years as determined by genetic risk score or family history and HLA genotype. Infants are randomised 1:1 to daily administration of ETHICS AND DISSEMINATION: The study was approved by the local ethical committees of the Technical University Munich, Medical Faculty, the Technische Universität Dresden, the Medizinische Hochschule Hannover, the Medical University of Warsaw, EC Research UZ Leuven and the Swedish ethical review authority. The results will be disseminated through peer-reviewed journals and conference presentations and will be openly shared after completion of the study. TRIAL REGISTRATION NUMBER: NCT04769037.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.